CA3180646A1 - New dry powder composition for peroral administration - Google Patents
New dry powder composition for peroral administrationInfo
- Publication number
- CA3180646A1 CA3180646A1 CA3180646A CA3180646A CA3180646A1 CA 3180646 A1 CA3180646 A1 CA 3180646A1 CA 3180646 A CA3180646 A CA 3180646A CA 3180646 A CA3180646 A CA 3180646A CA 3180646 A1 CA3180646 A1 CA 3180646A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- treatment
- respiratory
- particles
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006079.4A GB202006079D0 (en) | 2020-04-24 | 2020-04-24 | New composition |
| GB2006079.4 | 2020-04-24 | ||
| PCT/GB2021/050994 WO2021214488A1 (en) | 2020-04-24 | 2021-04-23 | New dry powder composition for peroral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180646A1 true CA3180646A1 (en) | 2021-10-28 |
Family
ID=71080269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180646A Pending CA3180646A1 (en) | 2020-04-24 | 2021-04-23 | New dry powder composition for peroral administration |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11844868B2 (https=) |
| EP (2) | EP4389212A3 (https=) |
| JP (2) | JP7387903B2 (https=) |
| KR (1) | KR20230005220A (https=) |
| CN (1) | CN115697309A (https=) |
| AU (1) | AU2021260923B2 (https=) |
| BR (1) | BR112022021511A2 (https=) |
| CA (1) | CA3180646A1 (https=) |
| DK (1) | DK4138790T3 (https=) |
| ES (1) | ES2976885T3 (https=) |
| GB (1) | GB202006079D0 (https=) |
| IL (1) | IL297373B1 (https=) |
| LT (1) | LT4138790T (https=) |
| MX (1) | MX2022013070A (https=) |
| PL (1) | PL4138790T3 (https=) |
| PT (1) | PT4138790T (https=) |
| SI (1) | SI4138790T1 (https=) |
| WO (1) | WO2021214488A1 (https=) |
| ZA (1) | ZA202211460B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| WO2023152503A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| JP2008502699A (ja) | 2004-06-14 | 2008-01-31 | セプラコール・インコーポレイテッド | 肺疾患治療方法、及びそのための組成物 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20080139483A1 (en) * | 2006-12-12 | 2008-06-12 | Gorczynski Richard J | Drug combination for hypertensive disorders |
| CN103476410B (zh) * | 2011-01-11 | 2020-02-21 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| WO2019183513A1 (en) | 2018-03-22 | 2019-09-26 | University Of Iowa Research Foundation | Compositions and methods for the treatment and prevention of muscular dystrophy |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
-
2020
- 2020-04-24 GB GBGB2006079.4A patent/GB202006079D0/en not_active Ceased
-
2021
- 2021-04-23 PL PL21724012.6T patent/PL4138790T3/pl unknown
- 2021-04-23 JP JP2022540540A patent/JP7387903B2/ja active Active
- 2021-04-23 CN CN202180042663.8A patent/CN115697309A/zh active Pending
- 2021-04-23 CA CA3180646A patent/CA3180646A1/en active Pending
- 2021-04-23 PT PT217240126T patent/PT4138790T/pt unknown
- 2021-04-23 DK DK21724012.6T patent/DK4138790T3/da active
- 2021-04-23 WO PCT/GB2021/050994 patent/WO2021214488A1/en not_active Ceased
- 2021-04-23 MX MX2022013070A patent/MX2022013070A/es unknown
- 2021-04-23 SI SI202130130T patent/SI4138790T1/sl unknown
- 2021-04-23 IL IL297373A patent/IL297373B1/en unknown
- 2021-04-23 EP EP24154507.8A patent/EP4389212A3/en active Pending
- 2021-04-23 BR BR112022021511A patent/BR112022021511A2/pt unknown
- 2021-04-23 AU AU2021260923A patent/AU2021260923B2/en active Active
- 2021-04-23 ES ES21724012T patent/ES2976885T3/es active Active
- 2021-04-23 LT LTEPPCT/GB2021/050994T patent/LT4138790T/lt unknown
- 2021-04-23 EP EP21724012.6A patent/EP4138790B1/en active Active
- 2021-04-23 KR KR1020227039916A patent/KR20230005220A/ko active Pending
-
2022
- 2022-03-17 US US17/696,984 patent/US11844868B2/en active Active
- 2022-10-19 ZA ZA2022/11460A patent/ZA202211460B/en unknown
-
2023
- 2023-10-23 US US18/491,946 patent/US12605341B2/en active Active
- 2023-11-15 JP JP2023194557A patent/JP2024020417A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL297373A (en) | 2022-12-01 |
| LT4138790T (lt) | 2024-04-10 |
| JP2023503178A (ja) | 2023-01-26 |
| ES2976885T3 (es) | 2024-08-12 |
| US20220202726A1 (en) | 2022-06-30 |
| US12605341B2 (en) | 2026-04-21 |
| EP4389212A3 (en) | 2024-10-09 |
| WO2021214488A1 (en) | 2021-10-28 |
| KR20230005220A (ko) | 2023-01-09 |
| JP7387903B2 (ja) | 2023-11-28 |
| EP4138790B1 (en) | 2024-01-31 |
| MX2022013070A (es) | 2022-11-30 |
| AU2021260923B2 (en) | 2026-03-12 |
| EP4138790A1 (en) | 2023-03-01 |
| JP2024020417A (ja) | 2024-02-14 |
| US20240269081A1 (en) | 2024-08-15 |
| SI4138790T1 (sl) | 2024-05-31 |
| PT4138790T (pt) | 2024-04-01 |
| EP4389212A2 (en) | 2024-06-26 |
| GB202006079D0 (en) | 2020-06-10 |
| PL4138790T3 (pl) | 2024-06-10 |
| ZA202211460B (en) | 2025-02-26 |
| CN115697309A (zh) | 2023-02-03 |
| US11844868B2 (en) | 2023-12-19 |
| BR112022021511A2 (pt) | 2023-01-24 |
| AU2021260923A1 (en) | 2022-12-08 |
| DK4138790T3 (en) | 2024-03-11 |
| IL297373B1 (en) | 2026-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12605341B2 (en) | Dry powder composition for peroral administration | |
| EP4138789B1 (en) | New delayed release composition for peroral administration | |
| US20230149362A1 (en) | New capsule composition for peroral administration | |
| HK40110823A (en) | New dry powder composition for peroral administration | |
| HK40088607A (en) | New dry powder composition for peroral administration | |
| HK40088607B (en) | New dry powder composition for peroral administration | |
| HK40090175A (en) | New delayed release composition for peroral administration | |
| HK40088609B (en) | New delayed release composition for peroral administration | |
| HK40088609A (en) | New delayed release composition for peroral administration | |
| EA049971B1 (ru) | Новая композиция с отсроченным высвобождением для перорального введения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250416 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250416 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250416 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250417 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250417 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250604 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250604 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250604 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250605 |